Skip to main content
Contact Us
Subscribe
E-Edition
68°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adaptive Biotechnologies
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
April 17, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
April 02, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
March 27, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
February 22, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
January 29, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
December 09, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
December 05, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 07, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
November 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Announces Launch of Epic Integration for clonoSEQ®
September 13, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
July 10, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
June 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
May 24, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
May 09, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
May 03, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
April 25, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
April 12, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
April 06, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
February 14, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
January 23, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
December 10, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
December 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Tickers
ADPT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.